Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Exploratory Evaluation of Technetium Tc 99m Tilmanocept by Intravenous (IV) Injection in Subjects With Liver Metastases From Colorectal Carcinoma Patients Using SPECT/CT Imaging Compared to FDG PET/CT Imaging

Trial Profile

An Exploratory Evaluation of Technetium Tc 99m Tilmanocept by Intravenous (IV) Injection in Subjects With Liver Metastases From Colorectal Carcinoma Patients Using SPECT/CT Imaging Compared to FDG PET/CT Imaging

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2018

At a glance

  • Drugs Tc 99m tilmanocept (Primary) ; Tc 99m tilmanocept (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Liver metastases
  • Focus Adverse reactions; Diagnostic use
  • Sponsors Navidea Biopharmaceuticals
  • Most Recent Events

    • 04 Oct 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2018.
    • 04 Oct 2018 Status changed from recruiting to active, no longer recruiting.
    • 12 Jul 2018 Planned End Date changed from 1 Mar 2018 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top